Our faculty secure major research grants from various National Institutes of Health as well as private sources.
A phase 3 double-blind study to evaluate the efficacy and safety of oral ozanimod compared to oral fingolimod in children and adolescents with relapsing-remitting multiple sclerosis. Michael Dwyer, III (Co-Investigator). Bristol Myers Squibb. $1,649,376. 6/1/2023-12/1/2032.
Clinical and Translational Science Award. Core Operations Special Populations. Ralph Benedict (Co-Investigator). NIH. $29,204,726. 1/1/2025-12/1/2031.
Selective galactosylceramidase ablation to study the pathogenesis of Krabbe leukodystrophy. Pablo Paez (Co-Investigator). National Institute of Neurological Disorders and Stroke (NINDS). $1,950,000. 2/1/2025-1/1/2030.
Selective galactosylceramidase ablation to study the pathogenesis of Krabbe leukodystrophy. Daesung Shin (Principal Investigator). NIH. $2,013,407. 12/1/2024-12/1/2029.
Molecular Mechanisms of Severe Diabetic Retinopathy. Sarah Zhang (Principal Investigator). National Eye Institute/NIH. $2,374,855. 9/1/2024-5/1/2029.
MRI-Based Quantitative Mapping of Oxygen Extraction Fraction in MS. Ferdinand Schweser (Co-Investigator). NIBIB. $1,773,283. 4/1/2024-3/1/2029.
Investigating the Action and Physiological Role of Slc4a11 in the Cornea. Michael Duffey (Co-Investigator). NIH National Eye Institute. $1,972,804. 2/1/2018-9/1/2028.
Investigating the Action and Physiological Role of Slc4a11 in the Cornea. Mark Parker (Principal Investigator). NIH National Eye Institute. 1/1/2018-9/1/2028.
A Multifactorial Mechanism for Alzheimer’s Disease. Zhen Yan (Principal Investigator). VA. $1,115,372. 10/1/2024-9/1/2028.
Prepare the mind: Can coaching in goal-directed behaviour increase the success of cognitive rehabilitation in people with MS?. Ralph Benedict (Consultant). National MS Foundation. 10/1/2024-9/1/2028.
The Role of the Bed Nucleus of the Stria Terminalis-Norepinephrine System in Amphetamine-type Stimulant Use Disorders. Jinwoo Park (Principal Investigator). NIH/NIDA. $3,225,662. 9/1/2023-6/1/2028.
Novel Inhibitors of Lysine Methyltransferases G9a and GLP for the Treatment of Alzheimer's Disease. Zhen Yan (Co-Investigator). NIA/NIH. $3,309,300. 9/1/2023-6/1/2028.
Programmable Hydrogels for Optimized Human Oligodendrocyte Transplantation in Demyelinating Disease. Fraser Sim (Co-Principal Investigator). National Institute of Neurological Disorders and Stroke (NINDS). $2,930,725. 7/1/2023-6/1/2028.
Regulatory mechanisms for retinal ganglion cell genesis. Xiuqian Mu (Principal Investigator). National Eye Institute. $2,311,139. 8/1/2023-4/1/2028.
Investigating the Action and Physiological Role of Slc4a11 in the Cornea. Sangita Patel (Co-Investigator). NIH National Eye Institute. $3,944,767. 2/1/2018-1/1/2028.
Epigenetics-Based Autism Treatment with Animal Models and Human Stem Cells. Zhen Yan (Principal Investigator). NINDS/NIH. $3,088,565. 2/1/2023-1/1/2028.
Epigenetics-Based Autism Treatment with Animal Models and Human Stem Cells. Jian Feng (Principal Investigator). NINDS. $1,544,283. 2/1/2023-1/1/2028.
A Ribozyme Rescue Strategy for Dry Age-Related Macular Degeneration. John Sullivan (Principal Investigator). VA Central Office. $330,000. 1/1/2025-12/1/2027.
Exercise Reset for Concussion - Modifying the Buffalo Concussion Protocol for Application in a Military Environment. John Leddy (Principal Investigator). Department of Defense (CDMRP). 1/1/2023-12/1/2027.